Clinical Trials Logo

Filter by:
NCT ID: NCT01127828 Completed - Quality of Life Clinical Trials

Effects of Cultura Yoghurt in Irritable Bowel Syndrome (IBS) Patients on Intestinal and Immunological Changes

Start date: September 2005
Phase: N/A
Study type: Interventional

To determine the effect of cultura probiotic yoghurt on number of responders to treatment during 8 weeks of treatment in comparison to placebo. To determine the effect of cultura yoghurt on change in total score of (IBS) irritable bowel syndrome severity index during 8 weeks of treatment in comparison to placebo in IBS out patients.

NCT ID: NCT01127750 Completed - Clinical trials for Relapsing Multiple Sclerosis

Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients

Start date: May 2010
Phase: Phase 3
Study type: Interventional

This study will assess tolerability and safety and health outcomes in relapsing MS patients taking FTY720.

NCT ID: NCT01127646 Terminated - Clinical trials for Attention Deficit Hyperactivity Disorder

A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents

EMD
Start date: June 2010
Phase: Phase 4
Study type: Interventional

The main purpose of the study is to help to understand the effect on children and adolescents who are stable on treatment with atomoxetine or osmotic-release oral system (OROS) methylphenidate for attention-deficit/hyperactivity disorder (ADHD) of not taking the medication for a maximum of 6 days over a 28-day study treatment period.

NCT ID: NCT01127633 Terminated - Alzheimer's Disease Clinical Trials

Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease

EXPEDITION EXT
Start date: December 2010
Phase: Phase 3
Study type: Interventional

This study is an open-label extension study in Alzheimer's patients who have completed participation in either solanezumab Clinical Trial H8A-MC-LZAM (NCT00905372) or H8A-MC-LZAN (NCT00904683).

NCT ID: NCT01126437 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease

Start date: May 2010
Phase: Phase 3
Study type: Interventional

Direct comparison studies of the tiotropium HandiHaler® 18 µg and Respimat® 5 µg formulations have been limited to 4-week crossover studies. Therefore, prospective data from a trial of adequate size and duration is required to establish that compared to tiotropium HandiHaler®, tiotropium Respimat® will have (a) similar effects on safety and (b) similar or superior effects on exacerbations.

NCT ID: NCT01125722 Completed - Overactive Bladder Clinical Trials

Clinical Trial to Study a Non-invasive Neurostimulation Device on Urgency (Urinary) Incontinence Overactive Bladder (OAB)

Start date: April 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether the non-invasive neurostimulation patch is effective in the treatment of urgency, frequency and urge (urinary) incontinence.

NCT ID: NCT01125189 Completed - Hepatitis C Virus Clinical Trials

Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients

HEPCAT
Start date: July 2010
Phase: Phase 2
Study type: Interventional

To establish that at least 1 dose of daclatasvir combined with standard of care (pegylated interferon and ribavirin) is safe and well tolerated and demonstrates extended rapid virologic response rates at least 35% greater than those with placebo.

NCT ID: NCT01124786 Completed - Clinical trials for Metastatic Pancreatic Adenocarcinoma

A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)

Start date: May 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether CO-1.01 is safe and effective in the treatment of patients with metastatic pancreatic cancer and low hENT1 expression compared with gemcitabine.

NCT ID: NCT01124344 Terminated - Major Depression Clinical Trials

Safety and Pharmacology Study of BMS-866949

Start date: May 2010
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to determine whether multiple doses.of BMS-886949 are safe and tolerable

NCT ID: NCT01122446 Completed - Type 1 Diabetes Clinical Trials

Diabetes Prevention - Immune Tolerance

DIAPREV-IT
Start date: April 2009
Phase: Phase 2
Study type: Interventional

A double-blind, randomized investigator-initiated study to determine the safety and the effect of Diamyd® on the progression to type 1 diabetes in children with multiple islet cell autoantibodies Eligible children are 4 years or older, have positive GAD-antibodies and at least one additional autoantibody and not yet diabetes. Objectives: DiAPREV-IT is the first prevention study with Diamyd®, where the drug is given before onset of type 1 diabetes. The primary objective is to demonstrate that Diamyd® is safe in children at risk for type 1 diabetes. The secondary objective is to evaluate if Diamyd® may delay or stop the autoimmune process leading to clinical type 1 diabetes in children with ongoing persistent beta-cell autoimmunity as indicated by multiple positive islet cell autoantibodies.